1. Generics Bulletin
  2. >>Business
  3. >>Deals

Revamped Amneal Would Consider A Transformational Deal

 
• By Aidan Fry

Amneal’s new management team is open to negotiating a major transaction, even as it looks to restore organic growth through a greater focus on differentiated generic and hybrid products.

Butterfly
Amneal's new management team would consider a transformation deal, but first it wants to transform the firm's operating base • Source: Shutterstock

Amneal Pharmaceuticals' newly installed management team under co-CEOs Chirag and Chintu Patel says it is open to evaluating potential merger and acquisition opportunities, “including transformational transactions”. However, the team’s immediate focus is on improving operational efficiencies and rationalizing costs.

Outlining plans to alleviate margin pressure , in part through better supply-chain management and facility utilization, Chirag –­ who will oversee Amneal’s commercial and business-development teams, with Chintu focusing on manufacturing, operations and research and development – pledged to “reinvigorate organic growth” by refocusing investments for both the group’s Generics and Specialty business segments on opportunities that offered the greatest return, such as hospital injectables and 505(b)(2) hybrid candidates

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.